r/100xpennystock

$CVX insider sell: Vice Chairman Mark A. Nelson sold $26.23M at $187.92
▲ 44 r/100xpennystock+9 crossposts

$CVX insider sell: Vice Chairman Mark A. Nelson sold $26.23M at $187.92

NELSON MARK A, Vice Chairman at Chevron, sold 139,600 shares at $187.92 per share, for roughly $26.23M, filed 2026-03-02. For a bearish read, that’s a high-significance insider sale at a fairly specific price level, and it puts a large block of stock on the tape from someone close to the business.

What makes it worth noting is the role and the size: this wasn’t a small director sale, but 139,600 shares from the Vice Chairman. Insiders sell for plenty of personal reasons, but large selling from a senior executive still deserves attention.

The 33-factor read on $$CVX with the calculated levels: $CVX

u/ExplanationNormal339 — 3 days ago
▲ 1 r/100xpennystock+1 crossposts

07/03/26 ~ .07 to $7 The Road To Project Nahoonai: Understanding How World-Class Infrastructure Is Built.

Ticker: CMC.V Exchange: TSXV
Ticker: CWSFF.QB Exchange OTC

One of the biggest misconceptions about major industrial projects is that they happen overnight.

In reality, projects like Project Nahoonai move through a series of important milestones: engineering, Indigenous partnerships, environmental work, feedstock agreements, financing, government support, strategic partnerships, construction, commissioning, and finally commercial operations.

As shareholders, it’s easy to focus on the daily share price. But long-term value is ultimately created through execution.

That’s the purpose of this community.

We’ll continue following Project Nahoonai objectively, tracking each milestone as it unfolds, recognizing meaningful progress when it’s earned, and holding management accountable to the commitments they make.

Infrastructure isn’t built on promises.

It’s built on execution.

Important Disclaimer:

My posts are not financial or investment advice. Please conduct your own due diligence before making any investment decisions. I am simply an individual on Reddit and X sharing my personal opinions, and they should be interpreted as such.

I do, however, want to emphasize that you are welcome to share this content across any form of media, including Reddit, X/Twitter, stock chat rooms, etc.

u/CryptoDev1 — 3 days ago

So ai found this ETF TWSC that is an ETF for TSM Just wast listed on June 26th and the volume is 0 right now that means each time someone buys shares the price will spike test my theory Reddit

u/electricalviber — 4 days ago
▲ 336 r/100xpennystock+2 crossposts

RZLV Rezolve AI NASDAQ CTB 180%. Low shares Count available to borrow, company setting up a $300 million buyback scheme to shrink the float. 45 million shares short currently. AGM Tomorrow and the last day of H1 !

The stock has been hammered down from over $8 a share since Fuzzy Panda shorted the stock with a catalogue of vague stories about the company and CEO.

Since then the revenue has grown from $46 million total in 2025. to $60 million revenue in the 1st quarter of 2026.

The company has confirmed they have annual recurring revenue of $232 million exiting 2025, with forecast revenue for 2026 of $360 million and an ARR of $500 million exiting 2027.

The AGM tomorrow is to outline the plan for the $300 million share buyback to reduce the float.

with am interest rate of 180% Apr to short, and the company planning to buy back between around 75 to 125 million shares(depending on price) and a total share count of only 400 million at the moment, the shorts have some work to do to get out In profit.

If you read Fizzys rational on X for shorting you can see how out of date they are, and what has been disproved with financial and relevant updates.

I'm very interested in the views of those on here who are often involved in looking for squeezes in the market and whether this stock ticks enough boxes.

reddit.com
u/jelentoo — 6 days ago
▲ 5 r/100xpennystock+6 crossposts

Growing from $31,000 to $630,000 in three months sharing my joy with everyone.

Account value: $630,482
3 month gain: +$602,317 (+2,243%)
Three months ago this account looked very different.
What people don't see on the chart are the days where I questioned every position, the pullbacks that made me want to hit the sell button, and the nights spent wondering if I was being too patient.
The funny part?
The biggest gains happened when I stopped obsessively checking the account.
Back in late March and April I was buried with work and barely looked at the market. Positions were already in place, so I just let them breathe. That ended up being the best decision I made.
No secret strategy. No crazy leverage. No YOLO all ins.
Just sticking with sectors I understood, adding when fear was high, and giving good positions time to work.
Most people underestimate how much money can be made by simply not interrupting a winning position.
I run a stock discussion group where I share free daily market analysis, including stock selection strategies, risk warnings, trading opportunities, and timing for entries. I share my strategies and experiences openly, hoping to help those eager to learn, seeking inspiration, or looking for different paths to financial freedom. If you are also pursuing financial freedom, feel free to contact me or share your thoughts. I love exchanging ideas and growing together. Please note that this article does not constitute investment advice. I read and reply to every private message. I’ve always been interested in learning how others approach short term trading and risk management.
Not financial advice. Just sharing my experience and interested in hearing how others would approach it.

u/Ok-Basil2753 — 5 days ago
▲ 8 r/100xpennystock+1 crossposts

Recommendations? New moonshot obsession required

After success with SLS and the rollercoaster ride with SRHX, I need a new obsession.

What are we recommending folks? If you could give me a small justification. It would be greatly appreciated.

Looking for stocks with big catalysts in the short/medium term.

Edit: still in SLS don’t worry 😂

reddit.com
u/IntroductionEast1326 — 6 days ago

$GRRR – Why I’m Bullish on Gorilla Technology

For anyone who hasn’t heard of Gorilla Technology ($GRRR) before, here’s why I think it’s one of the most misunderstood AI infrastructure companies on the market.

Most people still think Gorilla is just another small AI software company. I don’t.

Over the past year, the company has been transforming into an AI infrastructure platform focused on sovereign AI, data centers, GPU compute, smart cities and critical infrastructure. More importantly, it’s beginning to convert signed contracts into real revenue.

A few things that caught my attention:

• Q2 2026 revenue is expected to be at least $44M, up from $28.2M in Q1 (+55% QoQ and over +100% YoY).

• The company announced a $2.5B five year GPUaaS contract, with financing covering roughly 70% of the required infrastructure.

• Gorilla continues expanding across Southeast Asia with AI infrastructure projects, including a 200MW AI data center campus.

• Instead of simply selling AI software, the company is building recurring revenue around AI infrastructure, sovereign AI, compute and long term platform deployments.

I think the market is still valuing GRRR like a speculative small cap instead of an infrastructure company with growing contracted revenue.
That’s why I’m invested.

Could execution disappoint? Absolutely. Every small cap carries risk. But if Gorilla continues converting contracts into revenue while scaling its infrastructure platform, I believe the valuation gap could close much faster than many expect.
This isn’t financial advice.

It’s simply why I’m bullish and why I’ll continue following the company closely.

🦍🦍🦍

reddit.com
u/Possible-Aioli8328 — 5 days ago
▲ 19 r/100xpennystock+8 crossposts

Upcoming catalysts 2026-2027

  1. Zynquista (sotagliflozin) Type 1 Diabetes NDA Resubmission

Timing: Mid-2026 (company guidance)

This is probably the biggest near-term catalyst. • Lexicon expects to resubmit the NDA for Zynquista in Type 1 Diabetes based on FDA feedback and safety data from the STENO1 study. • Management has stated that a resubmission is anticipated in mid-2026, with the possibility of FDA approval later in 2026 if the required exposure and DKA safety data are achieved. 

Why it matters: A successful resubmission would reopen a large commercial opportunity that investors have largely discounted after prior regulatory setbacks.

  1. SONATA-HCM Phase 3 Enrollment Completion

Timing: Mid-2026

Lexicon’s pivotal SONATA-HCM trial is evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM). • Enrollment of approximately 500 patients is expected to be completed by mid-2026. • The trial is running across roughly 130 sites in 20 countries. 

Why it matters: Completion of enrollment significantly de-risks execution and puts investors on a shorter timeline to the data readout.

  1. SONATA-HCM Topline Data

Timing: Q1 2027

While slightly beyond the next six months, many investors will begin positioning for this event during 2026. • Lexicon continues to guide to Q1 2027 topline results. 

Why it matters: Positive data could create an entirely new indication for sotagliflozin and potentially transform the valuation of the company.

  1. Pilavapadin (LX9211) Partnership Announcement

Timing: Potentially anytime in 2026

Pilavapadin is Lexicon’s non-opioid neuropathic pain candidate. • The FDA End-of-Phase 2 meeting was completed successfully. • Management has repeatedly stated that it is pursuing partnership discussions. 

Why it matters: A licensing deal could bring: • Upfront cash • Development funding • Validation of the program

Given Lexicon’s size, a partnership announcement could be a major stock-moving event.

  1. Novo Nordisk LX9851 Milestones

Timing: Throughout 2026

LX9851 is an oral obesity asset licensed to Novo Nordisk. • Lexicon has already received milestone payments and says it may receive up to an additional $20 million of milestones during 2026.  • Novo initiated Phase 1 development in 2026. 

Why it matters: These are non-dilutive cash inflows and help fund operations without equity issuance.

  1. International Sotagliflozin Approvals

Timing: Throughout 2026

Viatris is responsible for commercialization outside the U.S. and Europe. • Regulatory filings have been submitted in markets including Canada, Australia, and New Zealand. • Lexicon expects additional approvals and submissions during 2026. 

Why it matters: Each approval further validates the asset and may generate commercial or milestone revenue.

reddit.com
u/Drunken_X — 6 days ago
▲ 92 r/100xpennystock+2 crossposts

GME vs SRXH short squeeze charts

Been talking to some people about the comparison between GME and SRXH shorts charts.

First image is SRXH currently, second is GME in 2021 squeeze, and third is comparing the two.

SRXH’s current reported short-interest profile is even more extreme than GameStop’s before its 2021 squeeze. GameStop peaked at approximately 109% reported short interest, while SRXH is currently reported at about 126%. That means the reported short position exceeds the number of shares outstanding, a rare situation that can increase the risk of a short squeeze if buying pressure rises.

The key difference is that high short interest alone doesn’t cause a squeeze. GameStop’s historic move also required sustained buying from retail investors, heavy options activity, and short sellers being forced to cover as the price rose. Without those catalysts, a stock can remain heavily shorted for an extended period.

If SRXH attracts significant buying demand or positive catalysts, short sellers may be forced to buy shares to close their positions, which can accelerate upward price moves. Whether that happens depends on future market activity and cannot be predicted from short-interest data alone. Thoughts?

Edit: not saying we should squeeze this. Simply asking for what others are seeing with the numbers.

u/Hungry_Builder9942 — 9 days ago
▲ 6 r/100xpennystock+4 crossposts

Financeability: Where Confidence Becomes Capital

u/CryptoDev1's "Project Nahoonai – The Complete Puzzle" prompted me to think more deeply about one particular piece: #14 – Financing & Partnerships.

The industry's focus is evolving from demand to financeability. Increasingly, confidence has become the foundation upon which capital is committed.

Financeability isn't simply about raising capital. It's about creating the confidence that attracts governments, Indigenous partners, lenders, strategic partners and long-term capital.

This is where disciplined execution begins to create a financeability advantage. Leadership. Engineering. Indigenous partnership. Carbon strategy. Commercial agreements. Execution. Each completed milestone systematically reduces risk, strengthens confidence and improves financeability.

A changing world is redefining capital, and systematic de-risking is becoming one of the strongest competitive advantages a project can build.

u/oilcan2012 — 6 days ago